Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia

jpedsurg.org

Pulmonary hypertension remains difficult to manage in congenital diaphragmatic hernia (CDH). Prenatal therapy may ameliorate postnatal pulmonary hypertension. We hypothesized that intra-amniotic (IA) injection of either sildenafil, a phosphodiesterase 5 inhibitor, or rosiglitazone, a PPAR-γ agonist, or both late in gestation would decrease the detrimental pulmonary vascular remodeling seen in CDH and improve peripheral pulmonary blood flow.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Jan 2024 · 1 min read

In brief

This study investigates intra-amniotic administration of sildenafil and rosiglitazone as prenatal interventions to reduce pulmonary vascular remodeling and improve blood flow in congenital diaphragmatic hernia. The research explores whether late-gestation pharmacologic treatment can mitigate the challenging pulmonary hypertension complications that persist after birth in CDH patients.

Pulmonary hypertension is a major management challenge in congenital diaphragmatic hernia (CDH).
Prenatal intra-amniotic therapy may reduce postnatal pulmonary hypertension in CDH.
Sildenafil (PDE5 inhibitor) and rosiglitazone (PPAR-γ agonist) are candidate prenatal therapies.
Late-gestation treatment aims to reverse pulmonary vascular remodeling and improve peripheral blood flow.
This approach represents a potential prenatal intervention strategy for CDH-associated pulmonary hypertension.

Written by the GCMD Library team from the article.

Read it at the source ↗